Actuate Therapeutics, Inc.

Healthcare · Biotechnology · United States

Last price 0.3351 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 18.43M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States. The company’s lead product candidate is elraglusib injection, a glycogen synthase kinase-3 inhibitor that is in Phase 2 trial to treat metastatic pancreatic ductal adenocarcinoma. It also develops elraglusib, which is in Phase 1/2 trial for the treatment of refractory pediatric malignancies, including Ewing sarcoma, as well as neuroblastoma and pediatric leukemias. The company was formerly known as Apothe...